A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
All News
Article
Article
As we have incorporated technology into our workflows, and consequently saved lives and suffering, we have balanced our excitement about progress with proof that incremental advances can truly deliver benefit. it is easy to let promise carry our caution away - and while most of the time such advances come in a vetted package, which we can consume without concern, conference abstracts come raw. This is the necessary ingredient to a platform which allows for bold ideas and innovation, but for that reason it is not such a curated space. At EULAR 2024, we saw the usual mix of bright, raw ideas on the poster floor emblematic of this paradigm.
Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA
Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
https://t.co/9twSiXYL3N https://t.co/9vz77SrVLt
Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs
ChatGPT in Rheumatology and Qualitative Research
Dr. Bella Mehta discusses abstract OP0158 presented at Eular 2024 in Vienna, Austria.
https://t.co/2EGLJdK2Pl https://t.co/AaRFqyo6jq
Planetary Health in Rheumatology
Dr. Antoni Chan interviews Dr. Nelly Ziade about her session Planetary Health, presented at Eular 2024 in Vienna, Austria.
https://t.co/gBkwyO1dWQ https://t.co/VvGqwi6tlJ
Top 10 Drug companies (revenue)
10 Regeneron $12.2b
9 Vertex $8.9b
8 Amgen $26.3b
7 Gilead $27.3b
6 Lilly $28.5b
5 BMS $46.2b
4 Merck $59.3b
3 AbbVie $58.1b
2 J&J $94.9b
1 Pfizer $100.3b https://t.co/GNlGToGcb1 https://t.co/OWyVUBzeO6
JAMA: 3 prospective cohort studies in USA show that multivitamin use by 390 124 healthy adults did not alter mortality risk (HR, 1.04; 95% CI, 1.02-1.07) https://t.co/VDxrI5Bskw https://t.co/o9wdITR0UT
Artificial Intelligence: Detection of CPPD on Hand Radiographs
Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. https://t.co/jQrwKXuaDc https://t.co/Ecv69wvHxA
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
Cognitive Function in Older Adults: Worse in Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
The path to new technologies in rheumatology must be beset with caution
https://t.co/rostCE3UFT https://t.co/bn352RmrN8
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease.
https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK
New Treatments for Systemic Sclerosis
aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z
ComOA- a cohort study from 3.4 million, 4 countries looked at OA (n=845K) & comorbidities. Tops were LBP (44%), HTN, (34%), allergy (21%), cataract (16%), vertigo (14%), depression (13%), DM (13%). After OA Dx: Fm, RA, PMR OP0230 #EULAR2024 https://t.co/GMVCHSfyt0 https://t.co/KFlacpHfAX
Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK
EULAR 2024 - Day 1 Report
https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8
Bella Mehta
Tweet
Planetary health session #EULAR2024
Need to consider these in managing patients.
We in healthcare are contributing to emissions significantly!
@RheumNow https://t.co/Gxyrm5drCE
